A population-wide profile of prescription drug use in Saskatchewan, 1989.
OBJECTIVE
To measure the prevalence of prescription drug use in Saskatchewan in 1989.


METHODS
Retrospective study.


METHODS
A total of 961,203 Saskatchewan residents (including those who died or were born during the study year) who were eligible for coverage under the Saskatchewan Prescription Drug Plan. The study population represented 94% of the province's total population; those excluded were mostly status Indians (for whom a federal plan is available).


RESULTS
At least one prescription was received by 66.0% of the study population in 1989. The mean number of prescriptions per patient was 8.2, and the mean cost of drug material per prescription was $13.95. Females received substantially more prescriptions than males; the difference was particularly notable for cardiovascular agents, antidepressants and benzodiazepines. In the senior population 80.8% received at least one prescription; the mean number of prescriptions per patient was 18.4. The most commonly dispensed drug for the entire study population was amoxicillin (290 prescriptions per 1000 people); triazolam was the most frequently dispensed central nervous system drug (74 prescriptions per 1000 people). Regional variation in overall drug use was remarkably small, although it increased at the drug-class level, especially for tranquillizers. The use of cardiovascular drugs was 27% to 32% higher (depending on how use was measured) per Regina resident than per Saskatoon resident. Benzodiazepines were commonly used on a long-term basis, despite recommendations to the contrary.


CONCLUSIONS
The results quantify the prevalence of prescription drug use, underscore the importance of careful management of drug therapy by physicians and pharmacists (especially for seniors), illustrate substantial variation in drug therapy strategies and raise questions about utilization of benzodiazepines and cardiovascular drugs.
Quinn
K
K
Policy and Health Economics Branch, Saskatchewan Health, Regina.
Baker
M J
MJ
Evans
B
B
D000367:Age Factors; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D002317:Cardiovascular Agents / Q000627:therapeutic use; D004358:Drug Therapy / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012525:Saskatchewan; D012737:Sex Factors
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D002317:Cardiovascular Agents; D001569:Benzodiazepines